Search

Your search keyword '"Pilmore, Helen L."' showing total 47 results
Start Over Author "Pilmore, Helen L."
47 results on '"Pilmore, Helen L."'

1. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Ahn, Curie, Alberú, Josefina, Baliker, Mary, Bamgboye, Ebun L., Barber, Thelma, Bensouda, Melissa, Chadban, Steve J., Dadhania, Darshana M., Dębska-Ślizień, Alicja, Devresse, Arnaud, Ditzen, Beate, Fowler, Kevin, Gill, John S., Jha, Vivekanand, Khairallah, Pascale, Knoll, Greg A., Korst, Uwe, Lee, Austin, Legendre, Christophe, Lentine, Krista L., Lerma, Edgar V., Lorenz, Elizabeth C., Matas, Arthur J., Mohan, Sumit, Nazarewski, Sławomir, Noronha, Irene L., Obrador, Gregorio T., Parekh, Rulan S., Pavlakis, Martha, Pascual, Julio, Pilmore, Helen L., Rosenkranz, Alexander R., Rozen-Zvi, Benaya, Roy-Chaudhury, Prabir, Tanabe, Kazunari, Wanner, Christoph, Wasse, Haimanot, Yang, Chul-Woo, Josephson, Michelle A., Becker, Yolanda, Budde, Klemens, Kasiske, Bertram L., Kiberd, Bryce A., Loupy, Alexandre, Małyszko, Jolanta, Mannon, Roslyn B., Tönshoff, Burkhard, Cheung, Michael, Jadoul, Michel, Winkelmayer, Wolfgang C., and Zeier, Martin

Published
2023
Full Text
View/download PDF

3. Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial

Author

Chadban, Steven J, Ying, Tracey, Gracey, David, Aouad, Leyla, Wyburn, Kate, Habijanec, Beatriz, Yeo, Hee-eun (Ellen), Lin, Lin, Rosales, Brenda, Hudaly, Julia, Rodrigues, Vera, Wong, Germaine, O'Connell, Philip, Murie, Penelope, Endre, Zoltan, Gray, Zuzana, Spicer, Rebecca, Durkan, Anne, Fahim, Magid A, Jegatheesan, Dev, Leary, Diana, Guo, Yujing (Sarah), Coburn, Amanda, Irvine, Rachael, McTaggart, Steven, Crawford, Aimee, Coates, P Toby, Hockley, Bronwyn, Fischer, Karen, Weinberg, Laurence, Mount, Peter, Baulch, Sarah, Claxton, Gayle, Harris, Saskia, Sidiropoulos, Sofia, Veenendal, Marieke, Kanellis, John, Barbis, Rita, Goodman, David, Brahmbhatt, Anjalee, Le Page, Amelia, Jamboti, Jagadish, Chiam, Anna, Warger, Anne, Lim, Wai H, Collins, Michael, Pilmore, Helen, Dittmer, Ian, Manley, Paul, Ahmed, Jafar, McConnochie, Rachael, Newby, Lynette, Chen, Yan, Simmonds, Catherine, Irvine, John, Usher, Jenny, Clark, Carolyn, Beckett, Claire, Prestidge, Chanel, Erickson, Robin, Rea, Miriam, Scherring, Claire, Collins, Michael G, Pascoe, Elaine M, Hawley, Carmel M, Johnson, David W, Varghese, Julie, Hickey, Laura E, Clayton, Philip A, Dansie, Kathryn B, McConnochie, Rachael C, Vergara, Liza A, Kiriwandeniya, Charani, Reidlinger, Donna, Mount, Peter F, McArthur, Colin J, Endre, Zoltan H, Howard, Kirsten, Howell, Martin, Jamboti, Jagadish S, Laurence, Jerome M, McTaggart, Steven J, O'Connell, Philip J, and Pilmore, Helen L

Published
2023
Full Text
View/download PDF

4. Baseline Characteristics and Representativeness of Participants in the BEST-Fluids Trial: A Randomized Trial of Balanced Crystalloid Solution Versus Saline in Deceased Donor Kidney Transplantation

Author

Collins, Michael G., Fahim, Magid A., Pascoe, Elaine M., Hawley, Carmel M., Johnson, David W., Varghese, Julie, Hickey, Laura E., Clayton, Philip A., Gill, John S., Dansie, Kathryn B., McConnochie, Rachael C., Vergara, Liza A, Kiriwandeniya, Charani, Reidlinger, Donna, Mount, Peter F., Weinberg, Laurence, McArthur, Colin J., Coates, P. Toby, Endre, Zoltan H., Goodman, David, Howard, Kirsten, Howell, Martin, Jamboti, Jagadish S., Kanellis, John, Laurence, Jerome M., Lim, Wai H., McTaggart, Steven J., O’Connell, Philip J., Pilmore, Helen L., Wong, Germaine, and Chadban, Steven J.

Published
2022
Full Text
View/download PDF

5. Challenges in the management of the kidney allograft: from decline to failure: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Author

Josephson, Michelle A., primary, Becker, Yolanda, additional, Budde, Klemens, additional, Kasiske, Bertram L., additional, Kiberd, Bryce A., additional, Loupy, Alexandre, additional, Małyszko, Jolanta, additional, Mannon, Roslyn B., additional, Tönshoff, Burkhard, additional, Cheung, Michael, additional, Jadoul, Michel, additional, Winkelmayer, Wolfgang C., additional, Zeier, Martin, additional, Ahn, Curie, additional, Alberú, Josefina, additional, Baliker, Mary, additional, Bamgboye, Ebun L., additional, Barber, Thelma, additional, Bensouda, Melissa, additional, Chadban, Steve J., additional, Dadhania, Darshana M., additional, Dębska-Ślizień, Alicja, additional, Devresse, Arnaud, additional, Ditzen, Beate, additional, Fowler, Kevin, additional, Gill, John S., additional, Jha, Vivekanand, additional, Khairallah, Pascale, additional, Knoll, Greg A., additional, Korst, Uwe, additional, Lee, Austin, additional, Legendre, Christophe, additional, Lentine, Krista L., additional, Lerma, Edgar V., additional, Lorenz, Elizabeth C., additional, Matas, Arthur J., additional, Mohan, Sumit, additional, Nazarewski, Sławomir, additional, Noronha, Irene L., additional, Obrador, Gregorio T., additional, Parekh, Rulan S., additional, Pavlakis, Martha, additional, Pascual, Julio, additional, Pilmore, Helen L., additional, Rosenkranz, Alexander R., additional, Rozen-Zvi, Benaya, additional, Roy-Chaudhury, Prabir, additional, Tanabe, Kazunari, additional, Wanner, Christoph, additional, Wasse, Haimanot, additional, and Yang, Chul-Woo, additional

Published
2023
Full Text
View/download PDF

6. Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial

Author

Collins, Michael G, primary, Fahim, Magid A, additional, Pascoe, Elaine M, additional, Hawley, Carmel M, additional, Johnson, David W, additional, Varghese, Julie, additional, Hickey, Laura E, additional, Clayton, Philip A, additional, Dansie, Kathryn B, additional, McConnochie, Rachael C, additional, Vergara, Liza A, additional, Kiriwandeniya, Charani, additional, Reidlinger, Donna, additional, Mount, Peter F, additional, Weinberg, Laurence, additional, McArthur, Colin J, additional, Coates, P Toby, additional, Endre, Zoltan H, additional, Goodman, David, additional, Howard, Kirsten, additional, Howell, Martin, additional, Jamboti, Jagadish S, additional, Kanellis, John, additional, Laurence, Jerome M, additional, Lim, Wai H, additional, McTaggart, Steven J, additional, O'Connell, Philip J, additional, Pilmore, Helen L, additional, Wong, Germaine, additional, Chadban, Steven J, additional, Ying, Tracey, additional, Gracey, David, additional, Aouad, Leyla, additional, Wyburn, Kate, additional, Habijanec, Beatriz, additional, Yeo, Hee-eun (Ellen), additional, Lin, Lin, additional, Rosales, Brenda, additional, Hudaly, Julia, additional, Rodrigues, Vera, additional, O'Connell, Philip, additional, Murie, Penelope, additional, Endre, Zoltan, additional, Gray, Zuzana, additional, Spicer, Rebecca, additional, Durkan, Anne, additional, Jegatheesan, Dev, additional, Leary, Diana, additional, Guo, Yujing (Sarah), additional, Coburn, Amanda, additional, Irvine, Rachael, additional, McTaggart, Steven, additional, Crawford, Aimee, additional, Hockley, Bronwyn, additional, Fischer, Karen, additional, Mount, Peter, additional, Baulch, Sarah, additional, Claxton, Gayle, additional, Harris, Saskia, additional, Sidiropoulos, Sofia, additional, Veenendal, Marieke, additional, Barbis, Rita, additional, Brahmbhatt, Anjalee, additional, Le Page, Amelia, additional, Jamboti, Jagadish, additional, Chiam, Anna, additional, Warger, Anne, additional, Collins, Michael, additional, Pilmore, Helen, additional, Dittmer, Ian, additional, Manley, Paul, additional, Ahmed, Jafar, additional, McConnochie, Rachael, additional, Newby, Lynette, additional, Chen, Yan, additional, Simmonds, Catherine, additional, Irvine, John, additional, Usher, Jenny, additional, Clark, Carolyn, additional, Beckett, Claire, additional, Prestidge, Chanel, additional, Erickson, Robin, additional, Rea, Miriam, additional, and Scherring, Claire, additional

Published
2023
Full Text
View/download PDF

9. Summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation

Author

Chadban, Steven J., Ahn, Curie, Axelrod, David A., Foster, Bethany J., Kasiske, Bertram L., Kher, Vijah, Kumar, Deepali, Oberbauer, Rainer, Pascual, Julio, Pilmore, Helen L., Rodrigue, James R., Segev, Dorry L., Sheerin, Neil S., Tinckam, Kathryn J., Wong, Germaine, Balk, Ethan M., Gordon, Craig E., Earley, Amy, Rofeberg, Valerie, and Knoll, Gregory A.

Published
2020
Full Text
View/download PDF

11. The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial

Author

Roberts, Matthew A., Cass, Alan, Garg, Amit X., Hawley, Carmel M., Ierino, Francesco L., Isbel, Nicole M., Krum, Henry, Pascoe, Elaine M., Perkovic, Vlado, Pilmore, Helen L., Tonkin, Andrew M., Vergara, Liza A., Levin, Adeera, Hare, David, Martin, Andrew, Wheeler, David C., Fulcher, Gregory, Brown, Helen, Colquhoun, David, Korczyk, Dariusz, Mather, Amanda, Wong, Andrew, Roberts, Matthew, Ierino, Francesco, Bisscheroux, Pascal, Gillies, Alastair, Garvey, Leanne, Tan, Ken-Soon, Lennan, Erica, Isbel, Nicole, Pitkin, Markus, Ahearn, Karin, Carroll, Robert P., Scott, Eileen, Cooper, Bruce, Pearse, Jacqueline, Snelling, Paul, Burman, Jenny, Hand, Samantha, Pedagogos, Eugenie, Karschimkus, Connie, Pilmore, Helen, Pilmore, Andrew, Walker, Robert, Ellis, Gaye, Marshall, Mark R., Paul, Cecilia, Johnson, David, Badve, Sunil, Helyar, Jean, Morrish, Alicia, Paul-Brent, Peta-Anne, Reidlinger, Donna, Scaria, Anish, Zhang, Lei, and Badve, Sunil V.

Published
2016
Full Text
View/download PDF

14. Interactions Between Donor Age and 12-Month Estimated Glomerular Filtration Rate on Allograft and Patient Outcomes After Kidney Transplantation

Author

Lim, Wai H., primary, Ooi, Esther, additional, Pilmore, Helen L., additional, Johnson, David W., additional, McDonald, Stephen P., additional, Clayton, Philip, additional, Hawley, Carmel, additional, Mulley, William R., additional, Francis, Ross, additional, Collins, Michael G., additional, Jaques, Bryon, additional, Larkins, Nicholas G., additional, Davies, Christopher E., additional, Wyburn, Kate, additional, Chadban, Steve J., additional, and Wong, Germaine, additional

Published
2022
Full Text
View/download PDF

26. Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial

Author

Roberts, Matthew A., primary, Darssan, Darsy, additional, Badve, Sunil V., additional, Carroll, Robert P., additional, Fahim, Magid A., additional, Haluska, Brian A., additional, Hawley, Carmel M., additional, Isbel, Nicole M., additional, Marshall, Mark R., additional, Pascoe, Elaine M., additional, Pedagogos, Eugenie, additional, Pilmore, Helen L., additional, Snelling, Paul, additional, Stanton, Tony, additional, Tan, Ken-Soon, additional, Tonkin, Andrew M., additional, Vergara, Liza A., additional, and Ierino, Francesco L. , additional

Published
2017
Full Text
View/download PDF

29. The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

Author

Roberts, Matthew A., Pilmore, Helen L., Lerino, Francesco L., Badve, Sunil V., Cass, Alan, Garg, Amit X., Hawley, Carmel M., Isbel, Nicole M., Krum, Henry, Pascoe, Elaine M., Tonkin, Andrew M., Vergara, Liza, Perkovic, Vlado, BLOCADE Study Collaborative Group, Roberts, Matthew A., Pilmore, Helen L., Lerino, Francesco L., Badve, Sunil V., Cass, Alan, Garg, Amit X., Hawley, Carmel M., Isbel, Nicole M., Krum, Henry, Pascoe, Elaine M., Tonkin, Andrew M., Vergara, Liza, Perkovic, Vlado, and BLOCADE Study Collaborative Group

Abstract

AimsThe Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study aims to determine the feasibility of a large-scale randomized controlled trial with clinical endpoints comparing the beta-blocking agent carvedilol with placebo in patients receiving dialysis.MethodsThe BLOCADE Feasibility Study is a randomized, double-blind, placebo-controlled, parallel group feasibility study comparing the beta-blocking agent carvedilol with placebo. Patients receiving dialysis for ≥3 months and who are aged ≥50 years, or who are ≥18 years and have diabetes or cardiovascular disease, were eligible. The primary outcome was the proportion of participants who complete a 6-week run-in phase in which all participants received carvedilol titrated from 3.125 mg twice daily to 6.25 mg twice daily. Other measures included how many patients are screened, the proportion recruited, the overall recruitment rate, the proportion of participants who remain on study drug for 12 months and the incidence of intra-dialytic hypotension while on randomized treatment.ResultsThe BLOCADE Feasibility Study commenced recruiting in May 2011 and involves 11 sites in Australia and New Zealand.ConclusionsThe BLOCADE Feasibility Study will inform the design of a larger clinical endpoint study to determine whether beta-blocking agents provide benefit to patients receiving dialysis, and define whether such a study is feasible.

Published
2015

30. Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.

Author

Roberts, Matthew A., Darssan, Darsy, Badve, Sunil V., Carroll, Robert P., Fahim, Magid A., Haluska, Brian A., Hawley, Carmel M., Isbel, Nicole M., Marshall, Mark R., Pascoe, Elaine M., Pedagogos, Eugenie, Pilmore, Helen L., Snelling, Paul, Stanton, Tony, Tan, Ken-Soon, Tonkin, Andrew M., Vergara, Liza A., and Ierino, Francesco L.

Subjects
HEMODIALYSIS patients, CARVEDILOL, BIOLOGICAL tags, ADRENERGIC beta blockers, ECHOCARDIOGRAPHY
Abstract

Background/Aims: Cardiac biomarkers are associated with cardiac abnormalities and adverse outcomes in dialysis patients. Our aim was to report the effect of the beta-blocker carvedilol on cardiac biomarkers in adult dialysis patients. Methods: The Beta-Blocker to Lower Cardiovascular Dialysis Events Feasibility Study was a randomized controlled trial comparing carvedilol to placebo. Serum and plasma were collected before the run-in, then 6 and 12 months post-randomization to measure B-type Natriuretic Peptide (BNP), N-terminal BNP (NT-ProBNP), high-sensitivity cardiac troponins I (hs-TnI) and T (hs-TnT), and galectin-3. Left ventricular global longitudinal strain (GLS) was measured by echocardiography at baseline. Results: Seventy-two participants were recruited of whom 49 completed the run-in and were randomized to carvedilol (n=26) or placebo (n=23). Baseline echocardiography demonstrated median (inter-quartile range) GLS of -14.27% (-16.63 to -11.93). NTproBNP and hs-TnT correlated with GLS (Spearman's rho=0.34 [p=0.018] and rho=0.28 [p=0.049], respectively). Median change scores from baseline to 12 months did not differ significantly between participants with complete biomarker data randomized to carvedilol (n=15) or placebo (n=16) for any biomarkers. Conclusions: NT-proBNP and hs-TnT were associated with GLS. However, changes in levels of the biomarkers from baseline to 12 months were not different between groups randomized to carvedilol and placebo. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

31. Challenges in blood pressure measurement in patients treated with maintenance hemodialysis

Author

Roberts, Matthew A., Pilmore, Helen L., Tonkin, Andrew M., Garg, Amit X., Pascoe, Elaine M., Badve, Sunil V., Cass, Alan, Ierino, Francesco L., Hawley, Camel M., Roberts, Matthew A., Pilmore, Helen L., Tonkin, Andrew M., Garg, Amit X., Pascoe, Elaine M., Badve, Sunil V., Cass, Alan, Ierino, Francesco L., and Hawley, Camel M.

Abstract

The association between blood pressure and cardiovascular outcomes in patients undergoing hemodialysis remains controversial. This may relate in part to the technique and device used and the timing of the blood pressure measurement in relation to the hemodialysis procedure. Emerging evidence indicates that standardized hemodialysis unit blood pressure measurements or measurements obtained at home, either by the patient or using an ambulatory blood pressure monitor, may offer advantages over routine hemodialysis unit blood pressure measurements for determining cardiovascular risk and treatment. This review discusses the available evidence and implications for clinicians and clinical trials.

Published
2012

44. End-stage renal failure in New Zealand Maori: An analysis of circulating transforming growth factor-β1.

Author

Anderson, Duane, Austin, Paul, and Pilmore, Helen L

Subjects
KIDNEY diseases, MAORI (New Zealand people), TRANSFORMING growth factors-beta, DISEASES
Abstract

SUMMARY: There is a high incidence of end-stage renal disease in New Zealand Maori. Reasons for this have not been established. Transforming growth factor-β1 (TGF-β1) is a profibrogenic cytokine, which stimulates the secretion of extracellular matrix components, and has been implicated in the pathogenesis of kidney failure. The aim of this study was to examine TGF-β1 in the serum of haemodialysis patients at our institution, in order to determine whether there was an upregulation of TGF-β1 in Maori. A TGF-β1-specific sandwich enzyme-linked immunosorbant assay was used to measure active TGF-β1 from the sera of 74 haemodialysis patients, and 19 healthy Maori without renal disease, diabetes or hypertension. In addition, clinical and laboratory markers were examined in the haemodialysis patients studied. There was no association between TGF-β1 and ethnicity in the groups studied. Transforming growth factor-β1 protein appeared to be inversely related to age, but was not associated with parameters of survival on dialysis such as serum albumin or measures of dialysis adequacy. Although there was a significantly higher incidence of type II diabetes mellitus in the Maori (P < 0.001) in comparison to European patients, the glycaemic control was comparable between the groups, as were all other laboratory and clinical parameters studied. This is the first study to examine the fibrogenic growth factor TGF-β1 in New Zealand Maori. Thus, an endogenous increase in TGF-β1 in Maori does not appear to be implicated in the increased incidence of end-stage renal disease in this population. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

45. Defining causes of death‐censored kidney allograft failure: A 5‐year multicentre ANZDATA and clinical cross‐sectional study.

Author

Mulley, William R., Hughes, Peter D., Collins, Michael G., Pilmore, Helen L., Clayton, Philip A., Wyld, Melanie L., Lee, Darren, van der Jeugd, Jane, Fernando, Sanduni C., Kuo, Stephanie Fang‐Tzu, Tan, Sarah, Jahan, Sadia, and Lim, Wai H.

Subjects
*SURGICAL complications, *GRAFT survival, *RENAL fibrosis, *KIDNEY transplantation, *HOMOGRAFTS, *KIDNEY failure
Abstract

Aim Methods Results Conclusion Determining specific causes of allograft failure allows a focus on understanding and treating these conditions. Previous studies highlight chronic antibody‐mediated rejection as a leading cause of late allograft failure. We sought to define causes of allograft failure in a large cohort of kidney transplant recipients across multiple centres in Australia and New Zealand, including cases previously attributed to chronic allograft nephropathy (CAN).All death‐censored allograft failures at 9 participating centres between 1 January 2014 to 31 December 2018 were included. Available clinical and biopsy data were reviewed and the “most likely” cause assigned.There were 642 death‐censored allograft failures in the study period. Of these, 495 (77.1%) had an informative biopsy performed a median of 13.4 months (IQR 2.5–39.1 months) prior to allograft failure. Rejection of any type was the leading cause of allograft failure (47.5%), comprised chiefly of chronic antibody‐mediated rejection (37.4%) and chronic T‐cell mediated rejection (6.4%). Other leading causes were undifferentiated interstitial fibrosis and tubular atrophy (10.8%), late medical and surgical complications (8.1%) and recurrent or de novo glomerulonephritis (7.0%). Polyoma viral nephropathy and calcineurin inhibitor toxicity each contributed to <2%. Causes of allograft failure previously attributed to CAN (n = 419, 65.3%) had a similar distribution to the overall cohort, with 43.9% attributed to chronic antibody‐mediated rejection.To prolong allograft survival, improved strategies are needed to curtail alloimmune responses. Greater understanding of the causes of undifferentiated interstitial fibrosis and tubular atrophy and potential treatments would also be of considerable benefit. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. End-stage renal failure in New Zealand Maori: An analysis of circulating transforming growth factor-β1.

Author

Anderson, Duane, Austin, Paul, and Pilmore, Helen L

Subjects
*KIDNEY diseases, *MAORI (New Zealand people), *TRANSFORMING growth factors-beta, *DISEASES
Abstract

SUMMARY: There is a high incidence of end-stage renal disease in New Zealand Maori. Reasons for this have not been established. Transforming growth factor-β1 (TGF-β1) is a profibrogenic cytokine, which stimulates the secretion of extracellular matrix components, and has been implicated in the pathogenesis of kidney failure. The aim of this study was to examine TGF-β1 in the serum of haemodialysis patients at our institution, in order to determine whether there was an upregulation of TGF-β1 in Maori. A TGF-β1-specific sandwich enzyme-linked immunosorbant assay was used to measure active TGF-β1 from the sera of 74 haemodialysis patients, and 19 healthy Maori without renal disease, diabetes or hypertension. In addition, clinical and laboratory markers were examined in the haemodialysis patients studied. There was no association between TGF-β1 and ethnicity in the groups studied. Transforming growth factor-β1 protein appeared to be inversely related to age, but was not associated with parameters of survival on dialysis such as serum albumin or measures of dialysis adequacy. Although there was a significantly higher incidence of type II diabetes mellitus in the Maori (P < 0.001) in comparison to European patients, the glycaemic control was comparable between the groups, as were all other laboratory and clinical parameters studied. This is the first study to examine the fibrogenic growth factor TGF-β1 in New Zealand Maori. Thus, an endogenous increase in TGF-β1 in Maori does not appear to be implicated in the increased incidence of end-stage renal disease in this population. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results